Biogen-Eisai go for another biomarker approval in Alzheimer's with lecanemab—and snag priority review

Biogen and Eisai’s follow-up to the Alzheimer’s disease treatment Aduhelm scored priority review under the FDA's accelerated review pathway, with a decision slated for Jan. 6.